Johnson & Johnson Reports Long-Term Efficacy Data for Icotyde in Treating Plaque Psoriasis
Johnson & Johnson (JNJ) announced new phase 3 data showing that patients with plaque psoriasis treated with its drug Icotyde achieved high levels of skin clearance after more than two years. The ICONIC-LEAD study, a placebo-controlled trial, found that at least 72% of participants experienced significant improvement in their condition over the long term. The results reinforce J&J's position in dermatology and suggest Icotyde could be an effective treatment option for patients with chronic plaque psoriasis. The data may support regulatory submissions or label expansions to include longer-term use, potentially increasing market adoption of the drug.
Tickers: $JNJ
Topics: clinical trials icotrokinra Johnson & Johnson plaque psoriasis